The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy

• Published in: Drugs in Context Vol. 7; pp. 212532 - 10
• Main Authors: Zhao, Yue, Singh, Rishi P
• Format: Journal Article
• Language: English
• Published: England BioExcel Publishing Ltd 13.08.2018
• Subjects: aflibercept; angiogenesis inhibitors; antibodies; bevacizumab; diabetic retinopathy; humanized antibodies; intravitreal injection; monoclonal; ranibizumab; Review; vascular endothelial growth factor A; aflibercept; bevacizumab; antibodies; monoclonal; intravitreal injection; angiogenesis inhibitors; diabetic retinopathy; vascular endothelial growth factor A; humanized antibodies; ranibizumab

Diabetes is a major cause of visual impairment among working-age adults in the United States. The proliferative form of diabetic retinopathy is associated with severe vision loss (acuity <5/200). The standard treatment in proliferative diabetic retinopathy (PDR) is panretinal photocoagulation (PR...